Silo Pharma, Inc. (SILO)
NASDAQ: SILO · Real-Time Price · USD
1.350
-0.140 (-9.40%)
At close: Feb 21, 2025, 4:00 PM
1.460
+0.110 (8.14%)
After-hours: Feb 21, 2025, 4:42 PM EST
Silo Pharma Employees
Silo Pharma had 3 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$24,034
Profits / Employee
-$1,261,145
Market Cap
6.05M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 3 | 0 | - |
| Dec 31, 2022 | 3 | 1 | 50.00% |
| Dec 31, 2021 | 2 | 1 | 100.00% |
| Dec 31, 2020 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
SILO News
- 4 days ago - Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment - GlobeNewsWire
- 11 days ago - Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia - GlobeNewsWire
- 4 weeks ago - Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment - GlobeNewsWire
- 7 weeks ago - Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain - GlobeNewsWire
- 2 months ago - Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia - GlobeNewsWire
- 3 months ago - Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management - GlobeNewsWire
- 3 months ago - Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders - GlobeNewsWire
- 4 months ago - Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant - GlobeNewsWire